Market Price

19.45 

0.12 0.6%

as of Aug 09 '22

52 Week Range:

17.14 33.01


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems worldwide. It also provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company offers Airvo 2, a humidified nasal high flow system; Optiflow, a nasal high flow therapy; and F&P 850 System, a noninvasive and invasive ventilation system. In addition, it provides infant respiratory products, such as resuscitation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. Further, the company offers hospital products, including humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, humidifiers, and accessories. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Equity (BVPS) 0.46
0.52
0.63
0.72
0.72
0.95
1.13
1.30
1.56
1.95
2.56
growth rate 13.0% 21.2% 14.3% 0.0% 31.9% 19.0% 15.0% 20.0% 25.0% 31.3%
Earnings BIT 72.75
113.00
143.50
170.08
211.08
240.10
269.80
316.00
379.30
712.30
505.60
growth rate 55.3% 27.0% 18.5% 24.1% 13.8% 12.4% 17.1% 20.0% 87.8% -29.0%
Avg.PE 19.05
18.98
24.45
45.33
62.91
49.11
57.43
64.49
108.33
44.22
21.49
growth rate -0.4% 28.8% 85.4% 38.8% -21.9% 16.9% 12.3% 68.0% -59.2% -51.4%
ROA 11.77
12.94
15.54
17.41
19.97
20.57
19.99
18.75
21.75
29.87
18.02
growth rate 9.9% 20.1% 12.0% 14.7% 3.0% -2.8% -6.2% 16.0% 37.3% -39.7%
ROE 19.38
21.39
24.94
25.80
28.32
28.11
26.73
24.99
30.45
42.03
23.55
growth rate 10.4% 16.6% 3.5% 9.8% -0.7% -4.9% -6.5% 21.9% 38.0% -44.0%
ROIC 15.29
16.58
20.06
23.05
26.41
25.82
24.47
22.81
27.36
38.32
22.12
growth rate 8.4% 21.0% 14.9% 14.6% -2.2% -5.2% -6.8% 20.0% 40.1% -42.3%
Cur. Ratio 1.29
2.36
1.82
2.08
1.91
2.40
2.38
2.47
1.55
2.15
2.92
growth rate 83.0% -22.9% 14.3% -8.2% 25.7% -0.8% 3.8% -37.3% 38.7% 35.8%
Quick Ratio 0.55
0.98
0.81
1.03
1.00
1.31
1.56
1.62
1.10
1.40
1.53
growth rate 78.2% -17.4% 27.2% -2.9% 31.0% 19.1% 3.9% -32.1% 27.3% 9.3%
Leverage 1.64
1.66
1.55
1.42
1.42
1.33
1.35
1.32
1.47
1.36
1.25
growth rate 1.2% -6.6% -8.4% 0.0% -6.3% 1.5% -2.2% 11.4% -7.5% -8.1%
Balance Sheet Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Acct.Receivable 78.00
83.00
94.71
109.29
133.24
131.60
147.70
159.30
223.30
228.90
182.70
growth rate 6.4% 14.1% 15.4% 21.9% -1.2% 12.2% 7.9% 40.2% 2.5% -20.2%
Acct.Payable 23.00
21.00
23.22
27.66
36.96
29.30
32.70
55.10
69.30
56.70
53.80
growth rate -8.7% 10.6% 19.1% 33.6% -20.7% 11.6% 68.5% 25.8% -18.2% -5.1%
Cur.Assets 195.00
215.00
234.96
243.29
285.72
349.10
424.20
455.30
518.70
920.00
887.90
growth rate 10.3% 9.3% 3.6% 17.4% 22.2% 21.5% 7.3% 13.9% 77.4% -3.5%
Total Assets 572.00
619.00
630.33
669.82
766.80
878.20
1,025.10
1,206.70
1,435.00
2,075.00
2,107.00
growth rate 8.2% 1.8% 6.3% 14.5% 14.5% 16.7% 17.7% 18.9% 44.6% 1.5%
Cash 6.00
8.00
10.44
13.62
18.74
61.30
31.90
48.20
67.10
97.30
89.90
growth rate 33.3% 30.5% 30.5% 37.6% 227.1% -48.0% 51.1% 39.2% 45.0% -7.6%
Inventory 84.00
89.00
94.48
96.14
120.95
135.00
125.40
136.10
146.50
270.60
358.90
growth rate 6.0% 6.2% 1.8% 25.8% 11.6% -7.1% 8.5% 7.6% 84.7% 32.6%
Cur.Liabilities 151.00
91.00
128.79
117.11
149.52
145.60
178.40
184.40
334.60
427.50
303.90
growth rate -39.7% 41.5% -9.1% 27.7% -2.6% 22.5% 3.4% 81.5% 27.8% -28.9%
Liabilities 224.00
246.00
224.20
198.63
225.13
216.60
263.70
293.50
461.20
554.10
427.30
growth rate 9.8% -8.9% -11.4% 13.4% -3.8% 21.8% 11.3% 57.1% 20.1% -22.9%
LT Debt 40.00
123.00
66.08
55.40
50.82
40.30
52.70
69.30
23.60
63.70
63.00
growth rate 207.5% -46.3% -16.2% -8.3% -20.7% 30.8% 31.5% -66.0% 169.9% -1.1%
Equity 274.40
298.60
406.12
471.19
541.67
661.60
761.40
913.20
973.80
1,520.90
1,679.70
growth rate 8.8% 36.0% 16.0% 15.0% 22.1% 15.1% 19.9% 6.6% 56.2% 10.4%
Common Shares 548.00
558.00
558.00
569.00
571.00
573.00
201.40
219.20
225.40
249.10
261.20
growth rate 1.8% 0.0% 2.0% 0.4% 0.4% -64.9% 8.8% 2.8% 10.5% 4.9%
Cash Flow Statement Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Capital Expenditures 65.00
59.00
27.31
39.27
48.02
47.90
83.20
115.40
145.30
160.20
138.40
growth rate -9.2% -53.7% 43.8% 22.3% -0.2% 73.7% 38.7% 25.9% 10.3% -13.6%
Cash Dividends 55.30
57.00
36.14
42.81
61.20
79.90
91.80
101.00
130.40
161.20
183.90
growth rate 3.1% -36.6% 18.5% 42.9% 30.6% 14.9% 10.0% 29.1% 23.6% 14.1%
Cash From OA 94.00
86.00
99.50
146.83
144.57
193.60
247.80
253.30
321.40
625.30
324.30
growth rate -8.5% 15.7% 47.6% -1.5% 33.9% 28.0% 2.2% 26.9% 94.6% -48.1%
FCF per Share 0.07
0.04
0.08
0.16
0.09
0.20
0.19
0.25
0.19
0.39
0.58
growth rate -42.9% 100.0% 100.0% -43.8% 122.2% -5.0% 31.6% -24.0% 105.3% 48.7%
Sale Purchase of Stock 0.65
2.11
1.57
1.60
1.80
growth rate 222.5% -25.6% 1.9% 12.5%
FCF 26.00
24.00
72.00
93.00
79.00
131.00
149.00
120.00
150.00
441.00
155.00
growth rate -7.7% 200.0% 29.2% -15.1% 65.8% 13.7% -19.5% 25.0% 194.0% -64.9%
Income Statement Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Sales 517.00
556.00
623.45
672.35
815.49
894.40
980.80
1,070.40
1,263.70
1,971.20
1,681.70
growth rate 7.5% 12.1% 7.8% 21.3% 9.7% 9.7% 9.1% 18.1% 56.0% -14.7%
Op.Income 64.00
113.00
143.50
170.08
211.08
240.10
269.80
316.00
379.30
712.30
505.60
growth rate 76.6% 27.0% 18.5% 24.1% 13.8% 12.4% 17.1% 20.0% 87.8% -29.0%
IBT 72.70
87.80
136.66
158.77
200.83
238.50
267.80
291.20
370.50
718.20
504.20
growth rate 20.8% 55.7% 16.2% 26.5% 18.8% 12.3% 8.7% 27.2% 93.9% -29.8%
Net Income 64.00
77.00
97.05
113.17
143.43
169.20
190.20
209.20
287.30
524.20
376.90
growth rate 20.3% 26.0% 16.6% 26.7% 18.0% 12.4% 10.0% 37.3% 82.5% -28.1%
EPS 0.12
0.14
0.17
0.20
0.25
0.29
0.33
0.36
0.49
0.90
0.65
growth rate 16.7% 21.4% 17.7% 25.0% 16.0% 13.8% 9.1% 36.1% 83.7% -27.8%
Gross Profit 275.00
308.00
365.40
410.98
521.65
590.40
650.40
715.80
835.80
1,245.60
1,052.70
growth rate 12.0% 18.6% 12.5% 26.9% 13.2% 10.2% 10.1% 16.8% 49.0% -15.5%
R&D 33.10
36.70
54.15
64.99
73.29
86.00
94.70
100.40
118.50
136.70
154.00
growth rate 10.9% 47.5% 20.0% 12.8% 17.4% 10.1% 6.0% 18.0% 15.4% 12.7%

Quarterly Statements

Item Name Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Earnings BIT 201.55
151.20
151.20
101.60
101.60
growth rate -25.0% 0.0% -32.8% 0.0%
Balance Sheet Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Acct.Receivable 228.90
248.60
248.60
182.70
182.70
growth rate 8.6% 0.0% -26.5% 0.0%
Acct.Payable 56.70
224.60
224.60
53.80
53.80
growth rate 296.1% 0.0% -76.1% 0.0%
Cur.Assets 920.00
867.70
867.70
887.90
887.90
growth rate -5.7% 0.0% 2.3% 0.0%
Total Assets 2,075.00
2,045.40
2,045.40
2,107.00
2,107.00
growth rate -1.4% 0.0% 3.0% 0.0%
Cash 97.30
103.20
103.20
89.90
89.90
growth rate 6.1% 0.0% -12.9% 0.0%
Inventory 270.60
291.80
291.80
358.90
358.90
growth rate 7.8% 0.0% 23.0% 0.0%
Cur.Liabilities 427.50
314.30
314.30
303.90
303.90
growth rate -26.5% 0.0% -3.3% 0.0%
Liabilities 554.10
454.60
454.60
427.30
427.30
growth rate -18.0% 0.0% -6.0% 0.0%
LT Debt 63.70
63.50
63.50
63.00
63.00
growth rate -0.3% 0.0% -0.8% 0.0%
Equity 1,520.90
1,590.80
1,590.80
1,679.70
1,679.70
growth rate 4.6% 0.0% 5.6% 0.0%
Common Shares 249.10
255.50
255.50
261.20
261.20
growth rate 2.6% 0.0% 2.2% 0.0%
Cash Flow Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Capital Expenditures 40.90
32.40
32.40
36.80
36.80
growth rate -20.8% 0.0% 13.6% 0.0%
Cash Dividends 43.91
52.21
52.21
39.74
39.74
growth rate 18.9% 0.0% -23.9% 0.0%
Cash From OA 203.60
63.75
63.75
98.40
98.40
growth rate -68.7% 0.0% 54.4% 0.0%
Sale Purchase of Stock
growth rate
FCF 162.70
31.35
31.35
61.60
61.60
growth rate -80.7% 0.0% 96.5% 0.0%
Income Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Sales 530.50
450.00
450.00
390.85
390.85
growth rate -15.2% 0.0% -13.1% 0.0%
Op.Income 201.55
151.20
151.20
101.60
101.60
growth rate -25.0% 0.0% -32.8% 0.0%
IBT 202.60
150.55
150.55
101.55
101.55
growth rate -25.7% 0.0% -32.6% 0.0%
Net Income 149.35
110.90
110.90
77.55
77.55
growth rate -25.7% 0.0% -30.1% 0.0%
Gross Profit 341.85
283.85
283.85
242.50
242.50
growth rate -17.0% 0.0% -14.6% 0.0%
R&D 36.05
37.85
37.85
39.15
39.15
growth rate 5.0% 0.0% 3.4% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (74.71)

YOY Growth Grade:

B (67.61)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 22.05 22.96 81.91
EPS / Growth 17.4% 0.85 -6.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 20.8%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 13.0% 13.0%
Future PE 2.00 24.07 24.07
Future EPS 0.94 2.89 2.89
Value Price
MOS %
0.46
-97.6%
17.16
-11.8%
17.16
-11.8%
MOS Price 0.23 8.58 8.58
IRT 20.59 10.55 10.55

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.